

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Addiction	4-Aminobutyrate aminotransferase (ABAT; GABA-AT)	<p>Rat studies identified a GABA-AT inactivator that could help treat cocaine addiction. In rats, oral treatment with the GABA-AT inactivator (1S,3S)-3-amino-4-difluoromethylethyl-1-cyclopentanoic acid (CPP-115) inhibited cocaine-induced dopamine increases and reward learning at lower doses than the marketed GABA-AT inactivator vigabatrin. In the rats, CPP-115 showed less retinal toxicity than vigabatrin. Next steps include clinical testing of the compound.</p> <p>Catalyst Pharmaceutical Partners Inc. has vigabatrin in Phase II/III testing to treat addiction.</p> <p>SciBX 4(48); doi:10.1038/scibx.2011.1358 Published online Dec. 15, 2011</p>	Composition of matter and use of CPP-115 has been patented; exclusively licensed to Catalyst Pharmaceutical Partners; available for partnerships	<p>Pan, Y. <i>et al. J. Med. Chem.</i>; published online Nov. 30, 2011; doi:10.1021/jm201231w</p> <p>Contact: Richard B. Silverman, Northwestern University, Evanston, Ill. e-mail: Agman@chem.northwestern.edu</p>